华中科技大学学报(医学版)
華中科技大學學報(醫學版)
화중과기대학학보(의학판)
ACTA UNIVERSITATIS MEDICINAE TONGJI
2010年
1期
50-54
,共5页
高随%习东%郭健文%严伟明%罗小平%宁琴
高隨%習東%郭健文%嚴偉明%囉小平%寧琴
고수%습동%곽건문%엄위명%라소평%저금
Fas%TNFR1%microRNA%细胞凋亡%重型肝炎
Fas%TNFR1%microRNA%細胞凋亡%重型肝炎
Fas%TNFR1%microRNA%세포조망%중형간염
Fas%TNFR1%microRNA%apoptosis%fulminant hepatitis
目的 构建人Fas(hFas)和人TNFR1(hTNFR1)基因的真核表达质粒pcDNA3.0-hFas、pcDNA3.0-hTNFR1和microRNA(miRNA)干扰质粒p-hFasmiRNA、 p-hTNFR1miRNA,初步验证其在体外细胞系对Fas和TNFR1基因表达的干预效应.方法 从人肝癌细胞HepG2细胞中获得模板cDNA,通过PCR扩增出hFas和hTNFR1全长片段,将目的 片段通过T载体过渡克隆至表达载体pcDNA3.0,得到重组质粒pcDNA3.0-hFas和pcDNA3.0-hTNFR1.利用miRNA设计软件,针对Fas和TNFR1基因分别设计3对pre-microRNA(pre-miRNA)序列,通过T4连接酶将pre-miRNA克隆至pcDNA6.2-GW/EmGFP-miRNA表达载体,同时构建非相关干扰质粒.构建成功的p-hFasmiRNA1、p-hFasmiRNA2、p-hFasmiRNA3和p-hTNFR1miRNA1、p-hTNFR1miRNA2、p-hTNFR1miRNA3分别与pcDNA3.0-hFas和pcDNA3.0-hTNFR1共转染至人293T细胞,通过Real-time PCR和Western blot检测转染48 h后对基因表达的干预效应.结果通过测序鉴定表明Fas和TNFR1基因的真核表达载体和miRNA干扰质粒均构建成功. Real-time PCR结果显示干预组的Fas和TNFR1基因的表达与对照组比较明显减少,抑制效率分别可达到87%和80%.Western blot结果也同样证实干预组的Fas和TNFR1基因的蛋白表达量与对照组比较明显减少.结论 成功构建了hFas和hTNFR1的真核表达载体和microRNA干扰质粒,并初步证实构建的microRNA干扰质粒在细胞水平对hFas和hTNFR1的表达具有特异性的抑制效应.
目的 構建人Fas(hFas)和人TNFR1(hTNFR1)基因的真覈錶達質粒pcDNA3.0-hFas、pcDNA3.0-hTNFR1和microRNA(miRNA)榦擾質粒p-hFasmiRNA、 p-hTNFR1miRNA,初步驗證其在體外細胞繫對Fas和TNFR1基因錶達的榦預效應.方法 從人肝癌細胞HepG2細胞中穫得模闆cDNA,通過PCR擴增齣hFas和hTNFR1全長片段,將目的 片段通過T載體過渡剋隆至錶達載體pcDNA3.0,得到重組質粒pcDNA3.0-hFas和pcDNA3.0-hTNFR1.利用miRNA設計軟件,針對Fas和TNFR1基因分彆設計3對pre-microRNA(pre-miRNA)序列,通過T4連接酶將pre-miRNA剋隆至pcDNA6.2-GW/EmGFP-miRNA錶達載體,同時構建非相關榦擾質粒.構建成功的p-hFasmiRNA1、p-hFasmiRNA2、p-hFasmiRNA3和p-hTNFR1miRNA1、p-hTNFR1miRNA2、p-hTNFR1miRNA3分彆與pcDNA3.0-hFas和pcDNA3.0-hTNFR1共轉染至人293T細胞,通過Real-time PCR和Western blot檢測轉染48 h後對基因錶達的榦預效應.結果通過測序鑒定錶明Fas和TNFR1基因的真覈錶達載體和miRNA榦擾質粒均構建成功. Real-time PCR結果顯示榦預組的Fas和TNFR1基因的錶達與對照組比較明顯減少,抑製效率分彆可達到87%和80%.Western blot結果也同樣證實榦預組的Fas和TNFR1基因的蛋白錶達量與對照組比較明顯減少.結論 成功構建瞭hFas和hTNFR1的真覈錶達載體和microRNA榦擾質粒,併初步證實構建的microRNA榦擾質粒在細胞水平對hFas和hTNFR1的錶達具有特異性的抑製效應.
목적 구건인Fas(hFas)화인TNFR1(hTNFR1)기인적진핵표체질립pcDNA3.0-hFas、pcDNA3.0-hTNFR1화microRNA(miRNA)간우질립p-hFasmiRNA、 p-hTNFR1miRNA,초보험증기재체외세포계대Fas화TNFR1기인표체적간예효응.방법 종인간암세포HepG2세포중획득모판cDNA,통과PCR확증출hFas화hTNFR1전장편단,장목적 편단통과T재체과도극륭지표체재체pcDNA3.0,득도중조질립pcDNA3.0-hFas화pcDNA3.0-hTNFR1.이용miRNA설계연건,침대Fas화TNFR1기인분별설계3대pre-microRNA(pre-miRNA)서렬,통과T4련접매장pre-miRNA극륭지pcDNA6.2-GW/EmGFP-miRNA표체재체,동시구건비상관간우질립.구건성공적p-hFasmiRNA1、p-hFasmiRNA2、p-hFasmiRNA3화p-hTNFR1miRNA1、p-hTNFR1miRNA2、p-hTNFR1miRNA3분별여pcDNA3.0-hFas화pcDNA3.0-hTNFR1공전염지인293T세포,통과Real-time PCR화Western blot검측전염48 h후대기인표체적간예효응.결과통과측서감정표명Fas화TNFR1기인적진핵표체재체화miRNA간우질립균구건성공. Real-time PCR결과현시간예조적Fas화TNFR1기인적표체여대조조비교명현감소,억제효솔분별가체도87%화80%.Western blot결과야동양증실간예조적Fas화TNFR1기인적단백표체량여대조조비교명현감소.결론 성공구건료hFas화hTNFR1적진핵표체재체화microRNA간우질립,병초보증실구건적microRNA간우질립재세포수평대hFas화hTNFR1적표체구유특이성적억제효응.
Objective To construct the eukaryotic expression plasmids of human Fas and TNFR1 gene(pcDNA3.0-hFas and pcDNA3.0-hTNFR1)and microRNA(miRNA)expression plasmid of hFas and hTNFR1 named p-hFasmiRNA and p-hTNFR1miRNA,and to investigate their inhibitory effects in vitro.Methods The eukaryotic expression plasmids of human Fas and TNFR1 gene were constructed(pcDNA3.0-hFas and pcDNA3.0-hTNFR1)and have been shown successfully to express hFas and hTNFR1 protein.miRNA expression plasmids of hFas and hTNFR1 named p-hFasmiRNA and p-hTNFR1miRNA complimentary to the sequence responsible for hFas and hTNFR1 respective were constructed,meanwhile irrelevant miRNA plasmid was used as a control.By respective co-transfection of p-hFasmiRNA and pcDNA3.0-hFas,p-hTNFR1 miRNA and pcDNA3.0-hTNFR1 expression construct into 293T cells,the inhibition of hFas and hTNFR1 expression was analyzed by real-time PCR and Western blot.Results The experiments showed the significant inhibitory effect of p-hFasmiRNA on hFas and p-hTNFR1miRNA on hTNFR1 expression at 48 h post-transfection both at RNA level and protein level as well in 293T cell lines with the inhibitory efficiency being as high as 87% for hFas and 80% for hTNFR1,respectively.Conclusion The p-hFasmiRNA and p-hTNFR1miRNA were constructed successfully,and it was verified that they could specifically inhibit the hFas and hTNFR1 expression at the cellular level.